Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021

Details

• Personal Author:
  Dooling, Kathleen ; Gargano, Julia W. ; Moulia, Danielle ; Wallace, Megan ; Rosenblum, Hannah G. ; Blain, Amy E. ; Hadler, Stephen C. ; Plumb, Ian D. ; Moline, Heidi ; Gerstein, Jack ; Collins, Jennifer P. ; Godfrey, Monica ; Campos-Outcalt, Doug ; Morgan, Rebecca L. ; Brooks, Oliver ; Talbot, H. Keipp ; Lee, Grace M. ; Daley, Matthew F. ; Oliver, Sara E.
• Corporate Authors:
  United States. Advisory Committee on Immunization Practices. ; CDC COVID-19 Response Team. ; Centers for Disease Control and Prevention (U.S.). Epidemic Intelligence Service. ; University of Arizona. College of Medicine. ; McMaster University. Faculty of Health Sciences. Department of Health Research Methods, Evidence, and Impact. ; Watts Healthcare Corporation. ; Vanderbilt University School of Medicine. ; Stanford University School of Medicine. ; Kaiser Permanente Colorado. Institute for Health Research.
• Description:
  What is already known about this topic? On August 23, 2021, the Food and Drug Administration granted full approval of the Pfizer-BioNTech COVID-19 vaccine for persons aged ≥16 years.
  
  What is added by this report? On August 30, 2021, after a systematic review of the data, the Advisory Committee on Immunization Practices revised its interim recommendation to a standard recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19.
  
  What are the implications for public health practice? Continued use of the Pfizer-BioNTech COVID-19 vaccine, now fully approved by the FDA in persons aged ≥16 years, is recommended based on increased certainty that its benefits (prevention of asymptomatic infection, COVID-19, and associated hospitalization and death) outweigh vaccine-associated risks. Suggested citation for this article: Self WH, Tenforde Suggested citation for this article: Dooling K, Gargano JW, Moulia D, et al. Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021. MMWR Morb Mortal Wkly Rep. ePub: 21 September 2021.
  
  mm7038e2.htm?s_cid=mm7038e2_w#contribAff
  
  mm7038e2-H.pdf
  
  
• Subjects:
  Adolescent Adult Advisory Committees Coronavirus Infections/prevention & Control COVID-19 Vaccines COVID-19/prevention & Control Drug Approval Immunization/standards Vaccination Viral Vaccines
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2021; v. 70 Early Release
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Journal Article
• Name as Subject:
  Pfizer-BioNTech COVID-19 vaccine
• Place as Subject:
  Alabama ; Arizona ; Colorado ; Indiana ; Los Angeles, CA ; Louisiana ; Maryland ; Minnesota ; New Mexico ; New York City, NY ; North Carolina ; Seattle, WA ; Utah
• Location:
  North America
• Pages in Document:
  5 pdf pages
• Volume:
  70
• Collection(s):
  Advisory Committee on Immunization Practices (ACIP) Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:3a123ef0f63cc87e3171a2a839e9618d55c1d5700d60f05a344e5c3a5a4f1a5c738a1f505818157f5308458ec3cde219f65c20f80d6c64894e54cf50b60623ae
• Download URL:
  https://stacks.cdc.gov/view/cdc/109943/cdc_109943_DS1.pdf
• File Type:
  [PDF - 333.70 KB ]